OBJECTIVES: URB937, a peripheral fatty acid amide hydrolase (FAAH) inhibitor, exerts profound analgesic effects in animal models. We examined, in rats, (1) the pharmacokinetic profile of oral URB937; (2) the compound's ability to elevate levels of the representative FAAH substrate, oleoylethanolamide (OEA); and (3) the compound's tolerability after oral administration. METHODS: We developed a liquid chromatography/tandem mass spectrometry (LC/MS-MS) method to measure URB937 and used a pre-existing LC/MS-MS assay to quantify OEA. FAAH activity was measured using a radioactive substrate. The tolerability of single or repeated (once daily for 2 weeks) oral administration of supramaximal doses of URB937 (100, 300, 1000 mg/kg) was assessed by monitoring food intake, water intake and body weight, followed by post-mortem evaluation of organ structure. KEY FINDINGS: URB937 was orally available in male rats (F = 36%), but remained undetectable in brain when administered at doses that maximally inhibit FAAH activity and elevate OEA in plasma and liver. Acute and subchronic treatment with high doses of URB937 was well-tolerated and resulted in FAAH inhibition in brain. CONCLUSIONS: Pain remains a major unmet medical need. The favourable pharmacokinetic and pharmacodynamic properties of URB937, along with its tolerability, encourage further development studies on this compound.
OBJECTIVES:URB937, a peripheral fatty acid amide hydrolase (FAAH) inhibitor, exerts profound analgesic effects in animal models. We examined, in rats, (1) the pharmacokinetic profile of oral URB937; (2) the compound's ability to elevate levels of the representative FAAH substrate, oleoylethanolamide (OEA); and (3) the compound's tolerability after oral administration. METHODS: We developed a liquid chromatography/tandem mass spectrometry (LC/MS-MS) method to measure URB937 and used a pre-existing LC/MS-MS assay to quantify OEA. FAAH activity was measured using a radioactive substrate. The tolerability of single or repeated (once daily for 2 weeks) oral administration of supramaximal doses of URB937 (100, 300, 1000 mg/kg) was assessed by monitoring food intake, water intake and body weight, followed by post-mortem evaluation of organ structure. KEY FINDINGS:URB937 was orally available in male rats (F = 36%), but remained undetectable in brain when administered at doses that maximally inhibit FAAH activity and elevate OEA in plasma and liver. Acute and subchronic treatment with high doses of URB937 was well-tolerated and resulted in FAAH inhibition in brain. CONCLUSIONS:Pain remains a major unmet medical need. The favourable pharmacokinetic and pharmacodynamic properties of URB937, along with its tolerability, encourage further development studies on this compound.
Authors: Satish Kathuria; Silvana Gaetani; Darren Fegley; Fernando Valiño; Andrea Duranti; Andrea Tontini; Marco Mor; Giorgio Tarzia; Giovanna La Rana; Antonio Calignano; Arcangela Giustino; Maria Tattoli; Maura Palmery; Vincenzo Cuomo; Daniele Piomelli Journal: Nat Med Date: 2002-12-02 Impact factor: 53.440
Authors: R Greco; T Bandiera; A S Mangione; C Demartini; F Siani; G Nappi; G Sandrini; A Guijarro; A Armirotti; D Piomelli; C Tassorelli Journal: Cephalalgia Date: 2015-01-21 Impact factor: 6.292
Authors: Guillermo Moreno-Sanz; Borja Barrera; Andrea Armirotti; Sine M Bertozzi; Rita Scarpelli; Tiziano Bandiera; Julio G Prieto; Andrea Duranti; Giorgio Tarzia; Gracia Merino; Daniele Piomelli Journal: Pharmacol Res Date: 2014-06-30 Impact factor: 7.658
Authors: Edward K Dziadulewicz; Stuart J Bevan; Christopher T Brain; Paul R Coote; Andrew J Culshaw; Andrew J Davis; Lee J Edwards; Adrian J Fisher; Alyson J Fox; Clive Gentry; Alex Groarke; Terance W Hart; Werner Huber; Iain F James; Adam Kesingland; Luigi La Vecchia; Yvonne Loong; Isabelle Lyothier; Kara McNair; Cathal O'Farrell; Marcus Peacock; Robert Portmann; Ulrich Schopfer; Mohammed Yaqoob; Jiri Zadrobilek Journal: J Med Chem Date: 2007-07-14 Impact factor: 7.446